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ABSTRACT 
Objective: The objective of the present research was to formulate and evaluate HPMC K4M, HPMC K100, and Carbopol 940 Mucoadhesive 
microspheres in combination with sodium alginate for controlling release of Nevirapine.  
Methods: Nevirapine microspheres were prepared by an Ionotropic gelation method using aluminium sulfate as a cross linking agent. The 
developed Nevirapine microspheres were characterized for Micromeritic properties, morphology, drug entrapment efficiency, in vitro wash off test, 
in vitro drug release, and interaction studies (Fourier transfer infrared spectroscopy (FTIR) & Differential scanning calorimetry (DSC).  
Results: The Nevirapine mucoadhesive microspheres were free-flowing and discrete. The mean particle size ranged from 705.21±2.00 to 
935.45±2.07 μm and the entrapment efficiencies ranged from 63.50 to 96.42 %. All the nevirapine microsphere batches showed good in vitro 
mucoadhesive property ranging from 03-68 % in the in-vitro mucoadhesive test after 8 h. FT-IR studies indicated the lack of nevirapine-polymer 
interactions in the nevirapine microspheres formulation. There were no compatibility issues and the crystallinity of nevirapine was found to be 
reduced in prepared mucoadhesive microspheres, which were confirmed by DSC and X-ray diffraction studies (XRD). Among different formulations, 
the nevirapine microspheres of batch F8 had shown the optimum percent drug entrapment and the controlled release of the nevirapine for about 12 
h (98.65%). The Release pattern of nevirapine from microspheres of batch F8 followed the Korsmeyer- peppas and zero-order release kinetic 
model. The value of ‘n’ was found to be 1.402, which indicates that the drug release was followed super case II transport type. Stability studies were 
carried out for F8 formulation at 4 °C/Ambient, 25±2 °C/60±5 %, 40±2 °C/75±5 % RH revealed that the drug entrapment and mucoadhesive 
behavior were within permissible limits.  
Conclusion: The results obtained in this present work demonstrate the potential use of HPMC K100 polymer for preparation of controlled delivery 
nevirapine mucoadhesive microspheres and prolonged residence at the absorption site. 
Keywords: HPMC K4M, HPMC K100M, Carbopol 940, Sodium alginate, Mucoadhesive microspheres, Nevirapine. 
 
INTRODUCTION  
Microcarriers technology offers an novel approach for drug delivery 
by coupling the drug to microcarrier particles, such as microspheres, 
microcapsules, liposomes, etc., which modify the release and 
absorption characteristics of the drug [1-3]. Microspheres possess 
important features among the particulate drug delivery systems by 
virtue of their small size and efficient carrier characteristics; 
however, the success of microspheres delivery system is limited due 
to their short residence time at the site of absorption [4]. It would 
therefore be advantageous to have the means for providing an 
intimate contact of the microspheres delivery system with absorbing 
biological membranes. This can be accomplished by coupling 
mucoadhesion characteristics to microspheres by using 
mucoadhesive polymer and developing mucoadhesive microspheres 
[5]. Mucoadhesive microspheres have advantages like efficient 
absorption, enhanced bioavailability of drugs, maximum utilization 
of drug, a much more intimate contact with mucus membrane, better 
patience compliance and drug targeting to absorption site can be 
executed by using suitable mucoadhesive polymers on the surface of 
microspheres [6]. The rationale behind the use of a mucoadhesive 
microsheres system is that, the application of bioadhesive 
microspheres with good bioadhesive properties would permit such 
microspheres to swell in contact with GIT mucosa to form a gel and 
control the rate of clearance from the GIT, thereby giving poorly 
absorbed drugs a longer time to be available at the absorptive 
surface. 
Nevirapine is an anti retroviral bioactive used in treatment of 
HIV/AIDS and viral diseases belongs to class II under BCS 
classification and exhibits low and variable oral bioavailability due 
to poor water solubility [7]. Nevirapine is a peptidomimetic inhibitor 
of both the HIV-1 and HIV-2 proteases [8]. Nevirapine requires 
control release due to its short biological half life (3-5 hrs), low 
bioavailability 65%, narrow therapeutic index and moreover it is 
primarily absorbed from stomach [9]. All the drawbacks 
necessitated the development of mucoadhesive microspheres for 
improving residence of dosage form in GIT which could utilize all the 
efficacy of Nevirapine, thereby reduce dosing frequency and 
enhance bioavailability. Therefore, mucoadhesive microspheres are 
promising candidate for delivery of Nevirapine for treatment of 
HIV/AIDS patients. The novelty of this work is in combining the 
advantage of particulate system (microsphere) and mucoadhesive 
drug delivery system by taking Sodium alginate and Mucoadhesive 
polymers i.e. HPMC K4, HPMC K100 and Carbopol 940. 
MATERIALS AND METHODS  
Materials 
Nevirapine was a gift sample from Aurobindo Pharma Ltd, Hyderabad. 
HPMC K4M, HPMC K100M, Carbopol 940 and Sodium alginate polymers 
were obtained from Karnataka Fine Chem Pvt. Ltd (Bangalore).  
Preparation of nevirapine mucoadhesive microspheres 
The Nevirapine mucoadhesive microspheres were prepared by 
Ionotropic external gelation technique [10, 11]. Nevirapine and 
mucoadhesive polymers were individually passed through sieve ≠ 80. 
The weighed quantity of the nevirapine was added to purified water 
containing the mucoadhesive polymers and thoroughly mixed with a 
stirrer at 400 rpm to form a homogenous polymer solution. The 
resulting dispersion was sonicated for 30 min to remove any air bubbles. 
For the formation of mucoadhesive microspheres the dispersion was 
extruded drop wise from a needle of 24 G in diameter from a height of 
about 5 cm into aqueous aluminium sulfate solution (10%) and stirred at 
400 rpm. The added droplets were retained in the aluminium sulfate 
solution for 30 min to complete the curing reaction and to produce 
spherical rigid nevirapine mucoadhesive microspheres [10]. Then the 
solution containing formed nevirapine microspheres was filtered by 
using Whatman filter paper. The mucoadhesive microspheres were 
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allowed to dry at 45 °C for 12 h. The composition of various nevirapine 
microspheres formulations was mentioned in Table1. 
Percentage yield 
The percentage yield of Nevirapine microspheres of various batches 
was calculated by using the weight of the final product after drying 
with respect to the initial total weight of the nevirapine and polymer 
used for preparation of nevirapine mucoadhesive microspheres. 
Particle size 
Particle size and size distribution of the Nevirapine mucoadhesive 
microspheres were calculated by sieve analysis method [12]. The 
Nevirapine mucoadhesive microspheres were separated into different 
size fractions (% weight fraction) by sieving for 10 min using standard 
sieves having nominal mesh opening of 1.4 mm, 1.2 mm, 1.0 mm, 0.85 
mm and 0.71 mm and the mean particle size was determined. 
Morphology of microspheres 
The surface morphology and shape of the Nevirapine microspheres 
were determined by scanning electron microscopy (SEM). The 
sample was mounted on a copper sample holder and sputter coated 
with platinum in an argon atmosphere. 
Drug entrapment efficiency 
The drug entrapment efficiency of nevirapine microspheres was 
estimated by dispersing the microspheres in 100 ml of 0.1N HCl buffer 
by vigorous shaking on mechanical shaker for 24h in order to extract 
the entrapped nevirapine completely.  
The solution was filtered and the nevirapine content in the filtrate was 
measured after suitable dilution by UV spectrophotometer at 284 nm 
(LABINDIA UV-3092 PC). 
 
Table 1: Composition of nevirapine mucoadhesive microspheres 
Formulation code Drug: polymer ratio Polymer ratio 
F1 1:0.5 0.25:0.25 (Sodium alginate: HPMC K4) 
F2 1:1 0.5:0.5 (Sodium alginate: HPMC K4) 
F3 1:1.5 0.75:0.75 (Sodium alginate: HPMC K4) 
F4 1:2 1:1 (Sodium alginate: HPMC K4) 
F5 1:0.5 0.25:0.25 (Sodium alginate: HPMC K100) 
F6 1:1 0.5:0.5 (Sodium alginate: HPMC K100) 
F7 1:1.5 0.75:0.75 (Sodium alginate: HPMC K100) 
F8 1:2 1:1 (Sodium alginate: HPMC K100) 
F9 1:0.5 0.25:0.25 (Sodium alginate: Carbopol 940) 
F10 1:1 0.5:0.5 (Sodium alginate: Carbopol 940) 
F11 1:1.5 0.75:0.75 (Sodium alginate: Carbopol 940) 
F12 1:2 1:1 (Sodium alginate: Carbopol 940) 
 
Mucoadhesive test 
The mucoadhesive property of nevirapine microspheres was 
evaluated by an in vitro adhesion testing method known as wash-off 
method. The freshly excised piece of the goat intestinal mucosa was 
mounted on the glass slide with cotton thread. About 100 
microspheres were spread onto each prepared glass slide and 
immediately thereafter the support was hang onto the arm of the 
USP disintegration machine.  
When the test apparatus was operated, the intestinal mucosa was 
given a slow, regular up and down movement in the test fluid (0.1N 
HCL buffer) at 37±0.5 °C. At an interval of 60 min up to 8 h the 
equipment was stopped and the number of nevirapine microspheres 
still sticking onto the intestinal mucosa was counted and percent 
mucoadhesion was calculated [13].  
In vitro dissolution 
The release of nevirapine from the mucoadhesive microspheres was 
studied in 0.1N HCl buffer pH 1.2 as medium using dissolution test 
apparatus paddle type at 37±0.5 °C and a rotating speed of 50 rpm. A 
sample of mucoadhesive microspheres equivalent to 100 mg of 
nevirapine was used in each test. 5 ml Aliquots were withdrawn 
through a filter (0.45 μ) from the dissolution apparatus hourly for 12 
h, and replaced with an equal volume of fresh dissolution medium. 
The samples were analyzed at 284 nm for nevirapine content using a 
UV spectrophotometer (LABINDIA UV-3092 PC) [14]. 
Release kinetic studies 
The rate and the mechanism of release of Nevirapine from the 
prepared mucoadhesive microspheres were analyzed by fitting the 
dissolution data into various kinetic models like zero order; first 
order, korsemeyer peppas, Higuchi’s model and Coefficient of 
correlation (r) values were calculated for the liner curves by 
regression analysis of the above plots. 
FTIR studies  
Fourier transforms infrared spectroscopy (FTIR) spectra of the pure 
Nevirapine, best formulation were produced using the KBr disk 
method. The samples were analyzed between wave numbers 4000 
to 400 cm-1 resolution. 
DSC studies 
The thermal behavior of pure nevirapine and nevirapine loaded 
microspheres were studied using a differential scanning calorimeter 
Shimadzu DSC 60 at a heating rate of 10 °C/min. 5 mg Samples were 
accurately weighed into aluminum pans and then sealed. The 
measurements were performed at a heating range of 50 °–400 °C 
under nitrogen atmospheres. 
X-ray diffraction study (XRD) 
The crystallinities of nevirapine, and nevirapine 
loaded mucoadhesive microspheres were evaluated by XRD 
measurement using an X-ray diffractometer (Brucker). All samples 
were measured in the 2ø angle range between 1–90 ° and with an 
interval of 0.1 by exposing them to Cuk α1 radiation (40 KV, 30 MA) 
and the scanning rate was 5 °/min. 
Stability study  
Stability studies were carried out for Nevirapine formulation as 
per ICH guidelines. The best mucoadhesive microspheres 
formulation (F8) was sealed in high density polyethylene bottles 
and stored at 4 °C/Ambient, 25±2 °C/60±5 %, 40±2 °C/75±5 % RH 
in closed for 90d. The samples (F8) were evaluated for entrapment 
efficiency and percentage mucoadhesion for every one month up 
to three months [15]. 
RESULTS AND DISCUSSION  
Percentage yield and Micromeritic studies 
The production yields of nevirapine microspheres prepared by 
the ionotropic gelation method were found to be between 83.33 
% to 93.23 % as shown in table 2. It was found that production 
yield of microspheres prepared by Carbopol 940 was greater 
than HPMC grades. All Nevirapine microspheres formulations 
were evaluated for micrometric properties. Results are shown in 
table 3.  
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Angle of repose of all microspheres batches varied from 22.72 to 
30.61. Compressibility index varies from 9.76 % to 14.08 %. 
Hausner’s ratio varies from 1.10 to 1.16. All formulations results 
revealed excellent flow property and compressibility. 
 















F1 83.33 63.50±0.75 705.21±2.00 22.72 09.76 1.10 
F2 87.15 72.27±1.11 723.33±2.42 24.40 10.66 1.11 
F3 89.80 78.42±1.62 749.38±1.25 25.73 11.42 1.11 
F4 91.03 85.66±1.67 785.80±2.61 27.49 11.86 1.11 
F5 85.47 71.72±0.75 774.58±1.70 23.45 10.53 1.11 
F6 88.85 79.06±1.00 816.49±1.10 24.92 12.04 1.13 
F7 91.04 84.45±1.54 863.13±2.54 27.80 12.70 1.14 
F8 92.37 91.48±1.67 901.08±1.91 28.79 13.89 1.16 
F9 86.13 77.87±0.79 799.58±1.91 25.17 10.97 1.12 
F10 89.35 85.88±1.00 837.52±2.21 26.85 11.77 1.12 
F11 91.56 91.52±1.18 883.92±2.09 28.79 12.78 1.14 
F12 93.23 96.42±1.67 935.45±2.07 30.61 14.08 1.16 
 
Particle size  
The average particle size of Nevirapine microspheres ranged from 
705.21±2.00 to 935.45±2.07 μm. The mean particle size was 
significantly increases with increasing mucoadhesive polymer 
concentration this may be attributed to the high viscosity of the 
mucoadhesive polymer solution [16]. 
Morphology of microspheres 
The morphology of the mucoadhesive microspheres of best 
formulation F8 was examined by scanning electron microscopy. The 
SEM photographs revealed that nevirapine microspheres were 
discrete (Fig.1) and spherical shape with a rough surface 
morphology [17]. 
Entrapment efficiency 
The percentage entrapment efficiency ranged from 63.50 to 96.42%. 
(table 2). The entrapment efficiency of the nevirapine microspheres 
prepared with Carbopol 940 was higher than those of microspheres 
prepared with HPMC grades. This may be attributed to higher 
molecular weight of Carbopol 940 than HPMC grades. An increase in 
the molecular weight of the polymer increases the entrapment 
efficiency of the mucoadhesive microspheres due to the formation of 







Fig. 1: Scanning electron photomicrographs of the Formulation (F3): a) 55 X, b) 500 X, c) 3000 X, d) 10000 X 
 
Mucoadhesive test 
The results of the in-vitro mucoadhesion studies of all nevirapine 
microsphere formulations were shown in table 4. Percentage 
mucoadhesion of nevirapine formulations increased with the 
increase in concentration of mucoadhesive polymers. The higher 
mucoadhesion of Carbopol 940 based mucoadhesive microspheres 
may be attributed to higher molecular weight of Carbopol 940 than 
HPMC K4 and HPMC K100 based microspheres. Our result is 
supported by the report of Robinson et al. [19].  
The solubility, hydration and mucoadhesiveness of the polymers 
depend on the pH of the in-vitro wash off medium.  
The results of the in-vitro wash-off test indicated that the nevirapine 
microspheres had fairly good mucoadhesive properties.  
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The developed nevirapine mucoadhesive microspheres would 
adhere to the Gastro intestinal walls, thus resisting gastric emptying 
and prolong the residence time at the absorption site, thereby 
improve and enhance the bioavailability [20, 21]. 
 
Table 4: Results of in vitro wash off test In 0.1 M HCL (pH 1.2)a 
Hours 1 2 4 6 8 
F1 95±1.52 85±2.08 53±0.57 32±1.15 03±0.57 
F2 97±1.15 87±1.52 61±0.57 39±1.00 12±1.15 
F3 100±0.57 93±1.52 67±1.15 47±1.52 22±1.73 
F4 100  98±1.15 71±1.00 56±0.57 34±1.52 
F5 97±1.00 89±0.57 71±1.52 57±0.57 36±1.15 
F6 100 97±0.57 80±1.00 64±1.15 45±1.52 
F7 100 99±1.53 88±1.00 71±1.15 57±0.57 
F8 100 100±0.57 90±1.52 77±1.15 64±0.57 
F9 100 96±0.57 83±1.15 66±1.52 45±1.55 
F10 100 100±0.57 87±1.15 72±1.00 54±1.52 
F11 100 100 93±0.57 79±1.00 62±1.53 
F12 100 100 95±0.57 82±1.52 68±1.00 
 
In vitro dissolution studies 
The in vitro Nevirapine release profiles for all batches was shown in 
fig. 2-3. Drug release from these mucoadhesive microspheres were 
slow, controlled release and dependent upon the nature and 
concentration of mucoadhesive polymers used [22,23]. It was found 
that there was decrease in nevirapine release with increase in 
mucoadhesive polymer content.  
This could be attributed to the greater degree of swelling upon hydration 
with greater mucoadhesive polymer content in the microspheres which 
leads to increase in the diffusional path length that slows down drug 
release. Among all the formulation F8 was chosen as the best 
formulation which containing HPMC K100M in combination with 
sodium alginate (1:2) showed good drug release profile in 12h (98.65%). 
Hence it is considered as the best microsphere formulation which seems 
to be a good candidate for controlled release. 
 
 
Fig. 2: Comparative release profile of formulation F1 to F6 
 
Release kinetic studies 
Drug release kinetic data for Nevirapine mucoadhesive 
microspheres were shown in table No.5. All the microsphere 
formulations (F1 to F12) followed the Korsmeyer-peppas model and 
zero-order release kinetic with regression values ranging from 0.928 
to 0.996. Korsmeyer-Peppas plots, ‘n’ value ranges from 0.388 to 
1.402 indicating that the Nevirapine release mechanism followed 
Anomalous and super case-II transport mechanism. 
 
Fig. 3: Comparative release profile of formulation F7 to F12 
 
FTIR studies & DSC studies 
IR Spectra of pure drugs sample of nevirapine were compared with IR 
spectra of nevirapine loaded Microspheres, as there was no significant 
change in the pattern of peaks of pure drug and nevirapine loaded 
Microspheres (Fig.4). Hence there was no interaction seen in between 
nevirapine and Mucoadhesive polymers.  
The thermal behavior of prepared nevirapine microspheres was studied 
in comparison with thermo grams of both pure nevirapine and drug 
loaded microspheres as shown in fig. 5. The thermogram of pure 
nevirapine showed a sharp endothermic peak at 245.6 °C, which 
corresponds to its melting point. The characteristic peak of nevirapine 
was well recognized in the nevirapine-loaded microspheres. Thus, there 
was no incompatibility between nevirapine and mucoadhesive polymers 
used in the formulation of microspheres. 
  
Table 3: Release kinetic parameter of nevirapine from mucoadhesive microspheres 
Formulation code Zero order First Order Higuchi Korsmeyer peppas n-value 
F1 0.996 0.868 0.969 0.978 0.388 
F2 0.992 0.780 0.954 0.970 0.835 
F3 0.987 0.767 0.944 0.964 0.952 
F4 0.992 0.800 0.956 0.980 1.017 
F5 0.996 0.778 0.964 0.983 0.924 
F6 0.992 0.799 0.955 0.982 1.066 
F7 0.988 0.778 0.940 0.990 1.239 
F8 0.974 0.697 0.905 0.979 1.402 
F9 0.975 0.725 0.912 0.932 0.870 
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F10 0.956 0.773 0.877 0.958 1.129 
F11 0.938 0.805 0.849 0.938 1.151 
F12 0.928 0.826 0.837 0.945 1.225 
 
 
Fig. 4: FTIR spectra of, (A): Pure Nevirapine; (B): Formulation containing K4M; (C): Formulation containing HPMC K100M; (D): 
Formulation containing Carbopol 940 
 
 
Fig. 4: DSC Thermogram of, (A): Nevirapine; (B): Best formulation F8  
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X-Ray diffraction study (XRD) 
The X-ray diffraction spectra’s was recorded for nevirapine and 
nevirapine loaded microspheres (F8) for investigating the 
crystalainity of the nevirapine in the mucoadhesive microspheres. 
The X-ray diffractogram of nevirapine showed sharp peaks at 6000 
depicting a typical crystalline pattern (fig. 5). However, nevirapine 
loaded mucoadhesive microspheres showed peaks, but of low 
intensity (3000), revealing that some amount of nevirapine was 
changed to amorphous form [24]. 
 
 
Fig. 5: XRD pattern of, (A): Pure Nevirapine; (B): Best formulation F8 
 
Table 6: Percentage entrapment efficiency and mucoadhesion of the F8 formulation 
Stability condition Sampling Day Percentage 





4 °C/Ambient 30 96.42±0.79  67.33±1.15 
60 96.05±0.67  65.67±1.53 
90 95.47±1.11  63.00±1.73 
25 °C/60 RH 30 96.13±1.00  68.00±1.53 
60 95.75±1.18  65.33±0.58 
90 95.14±1.54  61.67±1.53 







amean±SD, n = 3. 
 
Stability study 
Stability studies of the prepared nevirapine mucoadhesive 
microspheres were carried out by storing the optimized formulation 
F8 at 4 °C/Ambient, 25±2 °C/60±5 %, 40±2 °C/75±5 % RH for 3 mo. 
The Best batch F8 show negligible change in entrapment efficiency 
and percentage mucoadhesion as shown in table 6. So it can be said 
that nevirapine mucoadhesive microspheres prepared with HPMC 
K100M is stable. 
CONCLUSION  
The present study has been satisfactorily attempted to formulate a 
mucoadhesive system of Nevirapine for oral administration with a 
view of enhancing bioavailability of the drug. From the experimental 
results, it can be concluded that, The IR & DSC spectra revealed that 
there was no interaction between polymers and Nevirapine, hence 
they are compatible. The prepared mucoadhesive microspheres of 
Nevirapine gave good micromeritic results. The particle size analysis 
revealed that all formulations gave particles in the range of 705.21 
to 933.45 µm which is suitable for oral administration of the 
formulation.  
Among all the formulation F8 was chosen as best formulation which 
containing HPMC K100M in combination with sodium alginate (1:2) 
showed the good entrapment efficiency (91.48%) mucoadhesion 
about (64 after 8h) and good drug release profile in 12h (98.65%). The 
drug release was erosion controlled as the plot of Pappas model was 
found to be linear. SEM analysis of the F8 microspheres revealed that 
the formulation was rough and spherical with ideal surface 
morphology. The prepared muco adhesive microspheres of Nevirapine 
will increase therapeutic efficacy by increasing patient compliance and 
provide controlled release which will overcome the drawbacks 
associated with the conventional therapy.  
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